CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
Sponsor: Barrow Neurological Institute
Listed as NCT03652181, this observational or N/A phase trial focuses on CCM and Cavernoma and remains completed. Sponsored by Barrow Neurological Institute, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Apr 2024 — Jul 2024 [monthly]
Completed
-
Feb 2024 — Apr 2024 [monthly]
Completed
-
Jan 2024 — Feb 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jun 2023 — Jan 2024 [monthly]
Active Not Recruiting
-
Jan 2022 — Jun 2023 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Nov 2021 — Jan 2022 [monthly]
Recruiting
-
Jan 2021 — Nov 2021 [monthly]
Recruiting
-
Oct 2019 — Jan 2021 [monthly]
Recruiting
-
Sep 2018 — Oct 2019 [monthly]
Recruiting
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Barrow Neurological Institute
- Johns Hopkins University
- Mayo Clinic
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of California, San Francisco
- University of Chicago
- University of New Mexico
- University of Utah
For direct contact, visit the study record on ClinicalTrials.gov .